Payment overview · 2025
General Payments
$1,316.04
50 reported records · 16 companies
Healthcare provider profile · identity verified
Tarek Sallam, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EAST MEADOW, NY · NPI 1235235565
Verified facts
What the public records show
CMS Open Payments records show Tarek Sallam, MD received $1,316.04 in general payments during 2025 across 50 reported records.
ABBVIE INC. accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xarelto by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $281.38 | 21.4% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $236.04 | 17.9% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $145.82 | 11.1% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $128.77 | 9.8% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $108.46 | 8.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $68.59 | 5.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.56 | 4.2% | 2 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $51.39 | 3.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.39 | 3.7% | 2 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $46.44 | 3.5% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $32.95 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.74 | 2.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.57 | 2.2% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $21.93 | 1.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.05 | 1.4% | 1 | 2025 |
| Fidia Pharma USA Inc. | Unresolved — no canonical attribution shown | $13.96 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,316.04 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $281.38 | 13 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc., Janssen Pharmaceuticals, Inc | $202.40 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $121.03 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $104.80 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $103.23 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $79.68 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $68.59 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $54.56 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $54.56 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $54.56 | 2 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $46.44 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $43.08 | 2 | 2025 |
Source payment records
|
|||||
| XGEVA Normalized: xgeva |
Biological | Amgen Inc. | $43.08 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $34.83 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $32.95 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.74 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $29.52 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.72 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.72 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| HYMOVIS Normalized: hymovis |
Device | Fidia Pharma USA Inc. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 135 | 36 |
| Losartan Potassium | Losartan Potassium | 134 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 114 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 85 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 28 |
| Metformin Hcl | Metformin Hcl | 78 | 23 |
| Mounjaro | Tirzepatide | 71 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 70 | 20 |
| Methylprednisolone | Methylprednisolone | 60 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 59 | 27 |
| Ozempic | Semaglutide | 55 | 13 |
| Glimepiride | Glimepiride | 53 | 18 |
| Gabapentin | Gabapentin | 49 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 49 | 19 |
| Omeprazole | Omeprazole | 48 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | 19 |
| Valsartan | Valsartan | 38 | 14 |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Mirtazapine | Mirtazapine | 35 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Lisinopril | Lisinopril | 29 | suppressed |
| Eliquis | Apixaban | 28 | suppressed |
| Folic Acid | Folic Acid | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | 18 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Meloxicam | Meloxicam | 22 | 16 |
| Allopurinol | Allopurinol | 21 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Famotidine | Famotidine | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Methocarbamol | Methocarbamol | 14 | 11 |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Furosemide | Furosemide | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,316.04 · 50 records | ABBVIE INC. | ABRYSVO, ACTHAR, AIRSUPRA, COMIRNATY, ENTYVIO, EVENITY, FARXIGA, HYMOVIS, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, KRYSTEXXA, MOUNJARO, OTEZLA, PREVNAR 20, PROLIA, REPATHA, RINVOQ, SPRAVATO, TAVNEOS, TONMYA, TRELEGY ELLIPTA, TREMFYA, The Cologuard Plus Collection Kit, XGEVA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error